1. Home
  2. CTMX vs LWLG Comparison

CTMX vs LWLG Comparison

Compare CTMX & LWLG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTMX
  • LWLG
  • Stock Information
  • Founded
  • CTMX 2008
  • LWLG 1991
  • Country
  • CTMX United States
  • LWLG United States
  • Employees
  • CTMX N/A
  • LWLG N/A
  • Industry
  • CTMX Biotechnology: Pharmaceutical Preparations
  • LWLG Containers/Packaging
  • Sector
  • CTMX Health Care
  • LWLG Industrials
  • Exchange
  • CTMX Nasdaq
  • LWLG Nasdaq
  • Market Cap
  • CTMX 596.2M
  • LWLG 560.5M
  • IPO Year
  • CTMX 2015
  • LWLG N/A
  • Fundamental
  • Price
  • CTMX $3.39
  • LWLG $4.82
  • Analyst Decision
  • CTMX Strong Buy
  • LWLG
  • Analyst Count
  • CTMX 5
  • LWLG 0
  • Target Price
  • CTMX $5.80
  • LWLG N/A
  • AVG Volume (30 Days)
  • CTMX 3.0M
  • LWLG 2.2M
  • Earning Date
  • CTMX 11-07-2025
  • LWLG 11-12-2025
  • Dividend Yield
  • CTMX N/A
  • LWLG N/A
  • EPS Growth
  • CTMX 263.20
  • LWLG N/A
  • EPS
  • CTMX 0.49
  • LWLG N/A
  • Revenue
  • CTMX $141,100,000.00
  • LWLG $94,355.00
  • Revenue This Year
  • CTMX N/A
  • LWLG N/A
  • Revenue Next Year
  • CTMX N/A
  • LWLG N/A
  • P/E Ratio
  • CTMX $6.79
  • LWLG N/A
  • Revenue Growth
  • CTMX 18.01
  • LWLG 4.52
  • 52 Week Low
  • CTMX $0.40
  • LWLG $0.79
  • 52 Week High
  • CTMX $3.91
  • LWLG $6.26
  • Technical
  • Relative Strength Index (RSI)
  • CTMX 57.06
  • LWLG 54.05
  • Support Level
  • CTMX $3.21
  • LWLG $4.23
  • Resistance Level
  • CTMX $3.50
  • LWLG $5.16
  • Average True Range (ATR)
  • CTMX 0.25
  • LWLG 0.50
  • MACD
  • CTMX -0.06
  • LWLG -0.10
  • Stochastic Oscillator
  • CTMX 35.42
  • LWLG 31.77

About CTMX CytomX Therapeutics Inc.

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

About LWLG Lightwave Logic Inc.

Lightwave Logic Inc is a United States-based development stage company moving toward commercialization of next-generation electro-optic photonic devices made on its P2IC technology platform which uses in-house proprietary high-activity and high-stability organic polymers. Electro-optical devices convert data from electric signals into optical signals for multiple applications. It designs and synthesizes organic chromophores for use in its own proprietary electro-optic polymer systems and photonic device designs.

Share on Social Networks: